Carregant...
Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF(V600E) Mutated Papillary Thyroid Cancer: Two Case Reports
Background: A multi-institutional, randomized phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer. Preclinical evidence and emerging clinical experience in other cancers support evaluating intermittent dosing of these two agents to ach...
Guardat en:
| Publicat a: | Thyroid |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Mary Ann Liebert, Inc.
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6874808/ https://ncbi.nlm.nih.gov/pubmed/28805135 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2017.0106 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|